Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
HOUSTON, May 31, 2017 -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7 at 2:00 p.m. EDT in New York, NY.
A live webcast of the presentation may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
Investors: Bellicum Pharmaceuticals Alan Musso, CFO 832-384-1116 [email protected] Media: BMC Communications Brad Miles 646-513-3125 [email protected]
